DekaBank Deutsche Girozentrale’s Avadel Pharmaceuticals AVDL Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$194K	–	1423
2021 Q3	$194K	Hold	20,000	–	–	﹤0.01%	1215
2021 Q2	$135K	Hold	20,000	–	–	﹤0.01%	1294
2021 Q1	$174K	Hold	20,000	–	–	﹤0.01%	1202
2020 Q4	$123K	Buy	+20,000	New	+$125K	﹤0.01%	1252
2017 Q1	–	Sell	-21,100	Closed	-$207K	–	964
2016 Q4	$207K	Buy	21,100 +1,600	+8%	+$17.6K	﹤0.01%	821
2016 Q3	$235K	Hold	19,500	–	–	﹤0.01%	805
2016 Q2	$210K	Buy	+19,500	New	+$208K	﹤0.01%	847
2016 Q1	–	Sell	-20,100	Closed	-$291K	–	1061
2015 Q4	$291K	Buy	20,100 +300	+2%	+$4.68K	﹤0.01%	801
2015 Q3	$323K	Buy	19,800 +800	+4%	+$17.6K	﹤0.01%	775
2015 Q2	$403K	Buy	19,000 +700	+4%	+$12.6K	﹤0.01%	744
2015 Q1	$329K	Buy	+18,300	New	+$287K	﹤0.01%	805

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

DekaBank Deutsche Girozentrale's AVDL Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Avadel Pharmaceuticals (AVDL) in Q4 2021, closing a stake of 20,000 shares — an estimated $194K sold.

DekaBank Deutsche Girozentrale first reported a position in AVDL in Q1 2015 and held it in 11 quarters. The position peaked at $403K in Q2 2015. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2021.

DekaBank Deutsche Girozentrale reported no remaining Avadel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 20,000 Avadel Pharmaceuticals shares in Q4 2021, an estimated $194K.
DekaBank Deutsche Girozentrale first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 11 quarters.
DekaBank Deutsche Girozentrale's Avadel Pharmaceuticals position peaked at $403K in Q2 2015.
83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.